Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
CRISPR Therapeutics revenue
CRISPR Therapeutics's revenue is $37.3 million.
What is CRISPR Therapeutics's revenue?
- CRISPR Therapeutics's revenue growth from 2015 to 2024 is 15,006.88%.
- CRISPR Therapeutics has 304 employees, and the revenue per employee ratio is $122,743.
- CRISPR Therapeutics's peak quarterly revenue was $898.8M in 2021(q2).
- CRISPR Therapeutics peak revenue was $915.0M in 2021.
- CRISPR Therapeutics annual revenue for 2023 was 371.2M, 30,885.48% growth from 2022.
- CRISPR Therapeutics annual revenue for 2024 was 37.3M, -89.95% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
CRISPR Therapeutics historical revenue
CRISPR Therapeutics's peak revenue was $915.0M in 2021. The peak quarterly revenue was $898.8M in 2021(q2).
CRISPR Therapeutics's revenue increased from $247.0k in 2015 to $37.3M currently. That's a 15,006.88% change in annual revenue.
CRISPR Therapeutics annual revenue
CRISPR Therapeutics annual revenue over time
| Fiscal year / year | CRISPR Therapeutics revenue |
|---|---|
| 2015 | $247,000 |
| 2016 | $5.2M |
| 2017 | $41.0M |
| 2018 | $3.1M |
| 2019 | $289,590 |
| 2020 | $719,000 |
| 2021 | $915.0M |
| 2022 | $1.2M |
| 2023 | $371.2M |
| 2024 | $37.3M |
Rate CRISPR Therapeutics' financial transparency
CRISPR Therapeutics annual growth
CRISPR Therapeutics saw the greatest revenue growth in 2021, when revenue increased by 127,154.94%.
CRISPR Therapeutics had the lowest revenue growth in 2022, when revenue changed by -99.87%.
CRISPR Therapeutics annual growth rate over time
| Year | CRISPR Therapeutics growth |
|---|---|
| 2016 | 1991%↑ |
| 2017 | 694%↑ |
| 2018 | -92%↓ |
| 2019 | -91%↓ |
| 2020 | 148%↑ |
| 2021 | 127155%↑ |
| 2022 | -100%↓ |
| 2023 | 30885%↑ |
| 2024 | -90%↓ |
CRISPR Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
CRISPR Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2016 | - | - | $1.5M | $2.3M |
| 2017 | $2.7M | $3.6M | $2.4M | $32.3M |
| 2018 | $1.4M | $1.1M | $563,821 | $114,862 |
| 2019 | $328,449 | $317,400 | $211.9M | $76.9M |
| 2020 | $156,865 | $44,000 | $148,035 | $194,099 |
| 2021 | $202,234 | $898.8M | $328,403 | $12.4M |
| 2022 | $178,144 | $158,000 | $94,000 | $6,000 |
| 2023 | $100.0M | $70.0M | - | $201.2M |
| 2024 | - | - | - | $35.7M |
CRISPR Therapeutics jobs nearby
Do you work at CRISPR Therapeutics?
Did CRISPR Therapeutics meet its revenue projections?
CRISPR Therapeutics financial information
| CEO | Samarth Kulkarni |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 304 |
| Date Founded | 2013 |
| Headquarters | Cambridge, Massachusetts |
| Revenue | $37.3M |
| Net Income | -$650,175,000 |
| Tax Rate | -0.0% |
| Total Assets | $2,243,057,000 |
| Ticker | CRSP |
CRISPR Therapeutics jobs you might like
CRISPR Therapeutics financing
CRISPR Therapeutics received early financing of $25.0M on 2014-04-24.
| Series | Round size | Date |
|---|---|---|
| Series B - CRISPR Therapeutics | $38M | 06/2016 |
| Funding Round - CRISPR Therapeutics | $64M | 04/2015 |
| Series A - CRISPR Therapeutics | $25M | 04/2014 |
CRISPR Therapeutics investors
| Investors | Security type |
|---|---|
| Wellington Capital Management | Series B - CRISPR Therapeutics |
| New Leaf Venture Partners | Series B - CRISPR Therapeutics |
| Clough Capital Partners | Series B - CRISPR Therapeutics |
| Franklin Templeton Investments | Series B - CRISPR Therapeutics |
| SR One | Funding Round - CRISPR Therapeutics |
| Versant Ventures | Funding Round - CRISPR Therapeutics |
| Abingworth | Funding Round - CRISPR Therapeutics |
| New Enterprise Associates (NEA) | Funding Round - CRISPR Therapeutics |
| Celgene | Funding Round - CRISPR Therapeutics |
| Versant Ventures | Series A - CRISPR Therapeutics |
CRISPR Therapeutics competitors
CRISPR Therapeutics's top competitor, Ardelyx, earned an annual revenue of $333.6M.
CRISPR Therapeutics's smallest competitor is Synlogic with revenue of $8.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Rigel Pharmaceuticals | - | $179.3M | 158 | - |
| Ardelyx | - | $333.6M | 86 | - |
| VBI Vaccines | - | $1.0M | 22 | - |
| Tango Therapeutics | - | $42.1M | 91 | - |
| eFFECTOR Therapeutics | - | $42.0M | 24 | - |
| Synlogic | - | $8,000 | 74 | - |
| Mersana Therapeutics | - | $40.5M | 169 | - |
| IDEAYA Biosciences | - | $7.0M | 69 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
CRISPR Therapeutics highest paying jobs
Zippia gives an in-depth look into the details of CRISPR Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about CRISPR Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at CRISPR Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by CRISPR Therapeutics. The data presented on this page does not represent the view of CRISPR Therapeutics and its employees or that of Zippia.
CRISPR Therapeutics may also be known as or be related to CRISPR THERAPEUTICS AG, CRISPR Therapeutics, CRISPR Therapeutics AG, Crispr Therapeutics and Crispr Therapeutics, Inc.